Erratum: Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption (Molecular Therapy (2025) 33(1) (104–118), (S1525001624006634), (10.1016/j.ymthe.2024.10.003))

Yanhong Jiang; Shuanghong Chen; Shenlin Hsiao; Haokun Zhang; Da Xie; Zi Jun Wang; Wendan Ren; Mingyao Liu; Jiaoyang Liao; Yuxuan Wu

doi:10.1016/j.ymthe.2024.11.031

Erratum: Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption (Molecular Therapy (2025) 33(1) (104–118), (S1525001624006634), (10.1016/j.ymthe.2024.10.003))

Yanhong Jiang
, Shuanghong Chen
, Shenlin Hsiao
, Haokun Zhang
, Da Xie
, Zi Jun Wang
, Wendan Ren
, Mingyao Liu^*
, Jiaoyang Liao^*
, Yuxuan Wu^*

^*此作品的通讯作者

生命科学学院

科研成果: 期刊稿件 › 评论/辩论

2 引用（Scopus）

摘要

(Molecular Therapy 33, 104–118; January 2025) In the originally published version of this article, there were errors in Figure 7E. The labeling of the PH1 group was incorrect. The label “PBS uninduced” was mistakenly spelled as “PBS induced,” and the PH1 group actually corresponds to the first three groups depicted in the figure. The authors apologize for any confusion.[Figure

源语言	英语
页（从-至）	417-418
页数	2
期刊	Molecular Therapy
卷	33
期	1
DOI	https://doi.org/10.1016/j.ymthe.2024.11.031
出版状态	已出版 - 8 1月 2025

访问文件

10.1016/j.ymthe.2024.11.031

其它文件与链接

链接到 Scopus 的出版物

指纹

探究 'Erratum: Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption (Molecular Therapy (2025) 33(1) (104–118), (S1525001624006634), (10.1016/j.ymthe.2024.10.003))' 的科研主题。它们共同构成独一无二的指纹。

引用此

Jiang, Y., Chen, S., Hsiao, S., Zhang, H., Xie, D., Wang, Z. J., Ren, W., Liu, M., Liao, J., & Wu, Y. (2025). Erratum: Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption (Molecular Therapy (2025) 33(1) (104–118), (S1525001624006634), (10.1016/j.ymthe.2024.10.003)). Molecular Therapy, 33(1), 417-418. https://doi.org/10.1016/j.ymthe.2024.11.031

@article{2afb0f569ffa4b8fad93a3b9493b2b58,

title = "Erratum: Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption (Molecular Therapy (2025) 33(1) (104–118), (S1525001624006634), (10.1016/j.ymthe.2024.10.003))",

abstract = "(Molecular Therapy 33, 104–118; January 2025) In the originally published version of this article, there were errors in Figure 7E. The labeling of the PH1 group was incorrect. The label “PBS uninduced” was mistakenly spelled as “PBS induced,” and the PH1 group actually corresponds to the first three groups depicted in the figure. The authors apologize for any confusion.[Figure",

author = "Yanhong Jiang and Shuanghong Chen and Shenlin Hsiao and Haokun Zhang and Da Xie and Wang, \{Zi Jun\} and Wendan Ren and Mingyao Liu and Jiaoyang Liao and Yuxuan Wu",

note = "Publisher Copyright: {\textcopyright} 2024 The American Society of Gene and Cell Therapy",

year = "2025",

month = jan,

day = "8",

doi = "10.1016/j.ymthe.2024.11.031",

language = "英语",

volume = "33",

pages = "417--418",

journal = "Molecular Therapy",

issn = "1525-0016",

publisher = "Cell Press",

number = "1",

}

Jiang, Y, Chen, S, Hsiao, S, Zhang, H, Xie, D, Wang, ZJ, Ren, W, Liu, M, Liao, J & Wu, Y 2025, 'Erratum: Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption (Molecular Therapy (2025) 33(1) (104–118), (S1525001624006634), (10.1016/j.ymthe.2024.10.003))', Molecular Therapy, 卷 33, 号码 1, 页码 417-418. https://doi.org/10.1016/j.ymthe.2024.11.031

Erratum: Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption (Molecular Therapy (2025) 33(1) (104–118), (S1525001624006634), (10.1016/j.ymthe.2024.10.003)). / Jiang, Yanhong; Chen, Shuanghong; Hsiao, Shenlin 等.
在: Molecular Therapy, 卷 33, 号码 1, 08.01.2025, 页码 417-418.

科研成果: 期刊稿件 › 评论/辩论

TY - JOUR

T1 - Erratum

T2 - Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption (Molecular Therapy (2025) 33(1) (104–118), (S1525001624006634), (10.1016/j.ymthe.2024.10.003))

AU - Jiang, Yanhong

AU - Chen, Shuanghong

AU - Hsiao, Shenlin

AU - Zhang, Haokun

AU - Xie, Da

AU - Wang, Zi Jun

AU - Ren, Wendan

AU - Liu, Mingyao

AU - Liao, Jiaoyang

AU - Wu, Yuxuan

PY - 2025/1/8

Y1 - 2025/1/8

N2 - (Molecular Therapy 33, 104–118; January 2025) In the originally published version of this article, there were errors in Figure 7E. The labeling of the PH1 group was incorrect. The label “PBS uninduced” was mistakenly spelled as “PBS induced,” and the PH1 group actually corresponds to the first three groups depicted in the figure. The authors apologize for any confusion.[Figure

AB - (Molecular Therapy 33, 104–118; January 2025) In the originally published version of this article, there were errors in Figure 7E. The labeling of the PH1 group was incorrect. The label “PBS uninduced” was mistakenly spelled as “PBS induced,” and the PH1 group actually corresponds to the first three groups depicted in the figure. The authors apologize for any confusion.[Figure

UR - https://www.scopus.com/pages/publications/85210394874

U2 - 10.1016/j.ymthe.2024.11.031

DO - 10.1016/j.ymthe.2024.11.031

M3 - 评论/辩论

C2 - 39610245

AN - SCOPUS:85210394874

SN - 1525-0016

VL - 33

SP - 417

EP - 418

JO - Molecular Therapy

JF - Molecular Therapy

IS - 1

ER -